Disease of skeletal motor system
Conditions
Interventions
Control group experimental group:Ropivacaine intra-articular injection
Affentanyl group:Alfentanyl plus ropivacaine intra-articular injection
Estroketamine group:Estramide plus ropivacaine intra-articular injection
Sponsors
The central hospital of Enshi tujia and miao autonomous prefesture
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) 18 years old = age = 65 years old; (2) Patients undergoing knee arthroscopy under elective general anesthesia; (3) ASA grade I ~ II; (4) No serious cardiovascular and cerebrovascular disease, normal liver and kidney function, no anesthetic allergy or other special medical history. Patients with any of the following exclusion criteria cannot be included in this study; (5) Patients or their families have a full understanding of the purpose and significance of this trial, voluntarily participate in this clinical trial and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) It is difficult to evaluate the curative effect of the patient's physical condition (such as severe central nervous system surgery or intracranial surgery)(2) Diabetes patients whose blood glucose has not been satisfactorily controlled (fasting blood glucose = 11.1mmol\/l in the screening period); (3) There was a history of myocardial infarction and unstable angina pectoris within 6 months before the screening period; (4) Patients with bradycardia (heart rate = 50 beats / min) and arrhythmia within 6 weeks before the screening period; Third degree atrioventricular block (excluding patients with pacemaker); (5) Patients with systolic blood pressure = 90mmHg or uncontrolled hypertension within 6 weeks before the screening period; (6) Patients with mental system diseases (such as schizophrenia, depression, etc.) and cognitive impairment; Patients with a history of epilepsy; Previous history of abuse of psychotropic drugs and narcotic drugs; (7) Abnormal coagulation function (Pt or PT-INR > 1.5 times the upper limit of normal value, APTT > 1.5 times the upper limit of normal value), bleeding tendency (such as active gastrointestinal ulcer) or being treated with thrombolysis or anticoagulation; (8) Abnormal liver function, ALT and \ / or ast > 1.5 times the upper limit of normal value; (9) Abnormal renal function, serum creatinine (CR) and \ / or urea nitrogen (BUN) > 1.5 times the upper limit of normal value; Dialysis patients; (10) Allergic to the ingredients or components of the tested drug; (11) Pregnant or lactating women; (12) Participate in clinical trials of other drugs within 3 months; (13) Patients with myasthenia gravis, schizophrenia and severe depression;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time of first postoperative analgesia; | — |
Secondary
| Measure | Time frame |
|---|---|
| Nrs-r within 24h (resting);NRS-M within 24h;Rebound pain;heart rate;blood pressure;Blood oxygen saturation;dizzy;hallucination;Drowsiness;nausea;vomit;skin Itch;diplopia;Sedation score;postoperative delirium; | — |
Countries
China
Contacts
Public ContactZhu Xianlin
The central hospital of Enshi tujia and miao autonomous prefesture
Outcome results
None listed